HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX: 13) announced on 5 November 2026 that the US Food and Drug Administration has granted Orphan Drug Designation to its oral Syk inhibitor sovleplenib for the treatment of autoimmune hemolytic anaemia (AIHA). The designation is the second the FDA has awarded to sovleplenib, following a primary immune thrombocytopenia (ITP) designation announced in October 2026. If sovleplenib ultimately receives FDA approval for AIHA, the designation would unlock seven years of US market exclusivity, alongside tax credits for qualified clinical trials and user fee waivers, all of which are significant commercial and financial incentives for investors to monitor.

Key Points

  • HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX: 13) — commercial-stage biopharmaceutical company focused on cancer and immunological disease therapies
  • US FDA grants Orphan Drug Designation to sovleplenib for autoimmune hemolytic anaemia, the company's second such designation for this asset
  • Designation confers eligibility for seven years of US market exclusivity upon approval, plus tax credits, user fee waivers, and specialised FDA regulatory guidance
  • Investors should watch progress of sovleplenib NDAs currently under NMPA review in China for both primary ITP and warm AIHA

Sovleplenib Secures Back-to-Back FDA Orphan Designations in ITP and AIHA Within Weeks

The FDA's Orphan Drug Designation programme applies to drugs intended for rare diseases affecting fewer than 200,000 people in the United States. Sovleplenib's first designation, for primary ITP, was disclosed in October 2026; the AIHA designation follows within weeks, reinforcing the breadth of the clinical programme HUTCHMED is pursuing with this asset. The company retains all worldwide rights to sovleplenib, meaning it would capture the full commercial benefit of any US approval without sharing exclusivity economics with a partner. This dual-designation position is a notable competitive development for the drug's pipeline profile.

AIHA: A Rare Autoimmune Blood Disorder With Meaningful Unmet Need

AIHA is an autoimmune disorder in which antibodies attack red blood cells, causing their destruction. The announcement states incidence is estimated at 0.8–3.0 per 100,000 adults per year, with a prevalence of approximately 17 per 100,000 adults and a death rate of 8–11%. Warm AIHA, the form studied in HUTCHMED's ESLIM-02 pivotal trial in China, accounts for approximately 75–80% of all adult AIHA cases. These epidemiological characteristics underpin the FDA's orphan classification and highlight an area where effective new oral therapies could address a genuine gap in treatment options.

China NDA Reviews for Sovleplenib in ITP and Warm AIHA Remain Active

Alongside the US regulatory progress, HUTCHMED's New Drug Applications for sovleplenib in both primary ITP and warm AIHA are currently under review by China's National Medical Products Administration. These submissions are supported by positive data from the pivotal ESLIM-01 trial in primary ITP and the ESLIM-02 trial in warm AIHA, respectively. Approval in China would represent a near-term commercial catalyst independent of any US regulatory timeline, given that HUTCHMED already markets four medicines in China and has established commercial infrastructure there.

Regulatory Incentives and Clinical Risk for HUTCHMED's Syk Inhibitor Programme

Beyond exclusivity, the FDA Orphan Drug Designation provides tax credits for qualified clinical trials and waivers of Prescription Drug User Fee Act charges, which can materially reduce development costs for a company of HUTCHMED's scale. However, the company's own disclosure cautions that forward-looking expectations around sovleplenib — including trial outcomes, regulatory approvals across jurisdictions, and commercial acceptance — involve material risks and uncertainties. Investors should note that orphan designation does not guarantee eventual FDA approval, and clinical or regulatory setbacks remain a specific risk for this asset.